Browsing by Author "Pavlovic, Mirjana (8970684700)"

Treatment of blood products by riboflavin and ultraviolet (UV) light prevents of white blood cell (WBC) replication and inactivates of pathogens. The aim of this study was to determine the effects of the inactivation by riboflavin and UV light upon plasma clinical performance, based on effect on the pretransfusion international normalized ratio (INR).A prospective, controlled randomized study included 60 patients who received transfusion of plasma on the Clinic for hematology of Clinical Centre in Nis. Experimental group (EG; 30 patients) was treated with Mirasol-inactivated fresh frozen plasma (FFP) and control group (CG; 30 patients) was transfused with noninactivated FFP. Besides pretransfusion vs. posttransfusion INR, the improvement in INR patient's plasma level per one FFP unit transfused was evaluated. Total of 68 units of FFP were transfused to patients of CG (2.24 ± 0.83. units per patient). Patients of EG received 84. units of Mirasol-inactivated plasma (i.e. 2.80 ± 1.19. units per patient). There was significant increase in number of FFP transfusions that normalized coagulation parameters in EG compared to CG (p=0.039). Also, there was a significant improvement of INR after every FFP unit application (p=0.046). We found a linear relationship between pretransfusion INR and improvement of INR (r=0.97; p<0.001).Plasma treated with riboflavin and UV light retains hemostatic competence and can be used efficiently in the therapy of congenital or acquired coagulopathies, but in larger quantity as compared to noninactivated FFP volume. © 2012 Elsevier Ltd.

Treatment of fresh frozen plasma (FFP) by riboflavin (RB) and ultraviolet (UV) light inhibits nucleic acid replication, leading to inactivation of white blood cells (WBCs) and pathogens. The goal of this study was to compare the effects of pathogen reduction technology (PRT) treatment on the plasma protein content based on biochemical, immune and hemostatic characteristics in "typical" pre-storage vs. post-storage PRT-treatment setting.Following whole blood centrifugation, separated plasma units were: (a) inactivated and frozen (pre-storage setting or control group [CG]) or (b) immediately frozen (post-storage setting or study group [SG]) afterward thawed, inactivated and stored at -40. ±. 5. °C (cryostorage). Plasma units were inactivated by the Mirasol PRT system (TerumoBCT, USA). Using multi-laboratory techniques and equipments, biochemistry (Advia 1800; Siemens, Germany), IgM, IgG and IgA, complement components C3 and C4 (BNA II nefelometer analyzer; Siemens, Germany), as well as CH50 activity (Behring coagulation timer; Siemens, Germany) were investigated. Procoagulant and inhibitor factors, such as antithrombin-III (AT-III), and protein C (PC) were determined by BCS XP Coagulation system (Siemens, Germany). There were neither significant changes in final protein levels, nor any differences in plasma immunoglobulin levels investigated. In the final samples CH50 activity was reduced in both investigated groups. The plasma concentration of the complement C3 following post-storage treatment was significantly (p<. 0.05) higher than in pre-storage setting. There was a trend of depletion of procoagulant activities in both, pre-storage and post-storage PRT-treatment (initial vs. final values), but there were no significant differences between two groups. Results confirmed that AT-III was significantly higher after post-storage inactivation.In conclusion, this study confirmed that there were not clinically relevant intergroup (pre-storage vs. post-storage PRT-treatment) differences in plasma constituent levels. Post-storage treated FFP remains, protein quantity, and activity well, and therefore can be used in clinical practice. Previously cryostored or quarantine FFP units (despite the reduced quarantine period after NAT/PCR testing) could be safely and effectively inactivated, directly prior to clinical application. © 2013 Elsevier Ltd.

AIM: To evaluate the clinical characteristics of splenic marginal-zone lymphoma (SMZL) following antigen expression and the influence of therapeutic approaches on clinical outcome and overall survival (OS). METHODS: A total of 30 patients with typical histological and immunohistochemical SMZL patterns were examined. Splenectomy plus chemotherapy was applied in 20 patients, while splenectomy as a single treatment-option was performed in 10 patients. Prognostic factor and overall survival rate were analyzed. RESULTS: Complete remission (CR) was achieved in 20 (66.7%), partial remission (PR) in seven (23.3%), and lethal outcome due to disease progression occurred in three (10.0%) patients. Median survival of patients with a splenectomy was 93.0 mo and for patients with splenectomy plus chemotherapy it was 107.5 mo (Log rank = 0.056, P > 0.05). Time from onset of first symptoms to the beginning of the treatment (mean 9.4 mo) was influenced by spleen dimensions, as measured by computerized tomography and ultra-sound ( t = 2.558, P = 0.018). Strong positivity (+++) of CD20 antigen expression in splenic tissue had a positive influence on OS (Log rank = 5.244, P < 0.05). The analysis of factors interfering with survival (by the Kaplan-Meier method) revealed that gender, general symptoms, clinical stage, and spleen infiltration type (nodular vs diffuse) had no significant ( P > 0.05) effects on the OS. The expression of other antigens (immunohistochemistry) also had no effect on survival-rate, as measured by a χ2 test ( P > 0.05). CONCLUSION: Initial splenectomy combined with chemotherapy has been shown to be beneficial due to its advanced remission rate/duration; however, a larger controlled clinical study is required to confirm our findings. © 2009 The WJG Press and Baishideng. All rights reserved.

Beside a supportive therapy of deficient blood component(s) by transfusions, hemotherapy involves the use of apheresis procedures due to plasma or blood cell collection (apheretic donation) and abnormal or excessive blood constituent removal or replacement, as well as to achieve an immunomodulatory or hemomodulatory effect (therapeutic apheresis—TAph). The basic goal of TAph is to reduce the “patients’ load” of pathogenic agents responsible for the development of disease to the levels that will allow clinical improvement. Hemotherapy also includes stem cell (SC) harvesting (for SC trans plants and use in regenerative medicine), as well as collection, ex vivo manipulation and (re)infusion of immune cells with a goal to obtain positive curative effect (by cell-mediated hemobiotherapy). Despite the development of chimeric antigen receptor T cell (CAR-T) expertise in hematooncology, solid tumors still represent a large therapeutic challenge. However, it is evident that cell-based therapy must remain an integral part of the treatment of cancers, including metastatic castrate-resistant prostate cancer (mCRPCa). For definite confirmation of initial clinical results, future randomized trials, with larger number of patients, are required. The objective of this chapter is to provide a systematic overview of current knowledge regarding TAph and to summarize evidence-based practical approaches related to cell-mediated hemobiotherapy of malignant disorders. © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2024.

Beside a supportive therapy of deficient blood component(s) by transfusions, hemotherapy involves the use of apheresis procedures due to plasma or blood cell collection (apheretic donation) and abnormal or excessive blood constituent removal or replacement, as well as to achieve an immunomodulatory or hemomodulatory effect (therapeutic apheresis—TAph). The basic goal of TAph is to reduce the “patients’ load” of pathogenic agents responsible for the development of disease to the levels that will allow clinical improvement. Hemotherapy also includes stem cell (SC) harvesting (for SC trans plants and use in regenerative medicine), as well as collection, ex vivo manipulation and (re)infusion of immune cells with a goal to obtain positive curative effect (by cell-mediated hemobiotherapy). Despite the development of chimeric antigen receptor T cell (CAR-T) expertise in hematooncology, solid tumors still represent a large therapeutic challenge. However, it is evident that cell-based therapy must remain an integral part of the treatment of cancers, including metastatic castrate-resistant prostate cancer (mCRPCa). For definite confirmation of initial clinical results, future randomized trials, with larger number of patients, are required. The objective of this chapter is to provide a systematic overview of current knowledge regarding TAph and to summarize evidence-based practical approaches related to cell-mediated hemobiotherapy of malignant disorders. © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2024.